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We describe three cases of bloodstream infection 
caused by colistin-resistant Escherichia coli in patients 
in a tertiary hospital in Italy, between August 2016 and 
January 2017. Whole genome sequencing detected the 
mcr-1 gene in three isolated strains belonging to dif-
ferent sequence types (STs). This occurrence of three 
cases with mcr-1-positive E. coli belonging to different 
STs in six months suggests a widespread problem in 
settings where high multidrug resistance is endemic 
such as in Italy.
A new plasmid-mediated transferable resistance deter-
minant, the mcr-1 gene, encoding a phosphoetha-nol-
amine transferase, has been described in November 
2015 by Liu et al. for the first time [1,2]. The plasmid 
carrying mcr-1 is mobilised to an Escherichia coli recipi-
ent by conjugation [1,2]. Since that description, the 
mcr-1 gene has been detected in isolates recovered 
from animals, in the food chain and in humans in many 
countries in Europe and in many other areas worldwide 
[3-8].
Here we describe three cases of human bloodstream 
infection in Italy caused by E. coli harbouring the mcr-1 
gene. All three patients were hospitalised in a 1,000-
bed hospital, in Pavia, in the period between August 
2016 and January 2017.
Case description
Case 1
In July 2016, a woman in her 70s with a pancreatic 
ductal carcinoma diagnosed 5 years earlier, was admit-
ted in a respiratory disease unit for pleural effusion. 
It was known that she had bone and liver metas-
tases, was splenectomised, and had received 18 
chemotherapy cycles in the previous 5 years. Four days 
after admission she experienced fever (38.8° C), vom-
iting and abdominal pain associated with increased 
inflammatory markers: procalcitonin 60 ng/mL (norm: 
0.00–0.50 ng/mL), C-reactive protein (CRP) 23.29 mg/
dL (norm: 0.00–0.50 mg/dL) and highly elevated white 
blood cells (WBC) 38.92 x 103 uL (norm: 4–10 x 103 uL). 
E. coli was isolated from urine and blood cultures. The 
two isolates showed the same antimicrobial suscepti-
bility profiles. Both showed resistance to colistin. The 
susceptibly profile of the isolate obtained from blood 
is shown in the Table.
The patient was empirically treated with merope-
nem intravenously and her clinical condition rapidly 
improved. She was discharged after 20 days of hospi-
talisation. She had never received previous treatment 
with colistin and did not report any previous close con-
tacts with farm animals. She had not travelled abroad 
since 2008.
Case 2
In August 2016, a woman in her mid-60 with a diag-
nosis of non-Hodgkin’s Lymphoma was admitted at the 
haematological unit of our hospital for distention of the 
ureter, renal pelvis and calices due to blockage of urine 
flow by bulky lymph nodes. She had been treated with 
two cycles of chemotherapy in the previous 6 weeks 
with poor response. She underwent nephrostomy after 
admission and one day later she developed fever (38.0° 
C) and chills. She had a severe pancytopenia with less 
than 0.800  x  103/uL (norm: 4–10  x  103 uL) WBC and 
increase of CRP 3.50 mg/dL (0.00–0.50 mg/dL).
The patient received intravenous empirical treatment 
with piperacillin/tazobactam and vancomycin. E. coli 
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was isolated from urine and blood cultures. As with 
Case 1, the two isolates obtained showed the same 
antimicrobial susceptibility profiles, both indicating 
resistance to colistin. The susceptibility profile of the 
isolate obtained from blood is shown in the Table.
The CRP decreased to normal range within 3 days and 
the fever disappeared within 24 hours. The patient 
died 5 days later due to a massive cerebral haemor-
rhage. She had never received previous treatment with 
colistin and did not report any previous close contact 
with farm animals. In the previous 12 years she had not 
travelled abroad.
Case 3
In January 2017, a woman in her early 80s with fever (> 
38.5° C), diarrhoea and abdominal pain was admitted 
at the infectious diseases unit of the same tertiary hos-
pital. In 2012, she underwent mastectomy and chemo-
therapy for breast cancer. Blood cultures were drawn 
upon admission and she received intravenous empiri-
cal treatment with piperacillin/tazobactam. E. coli was 
isolated from blood cultures. The Table shows the anti-
microbial profile; the strain was colistin-resistant but 
susceptible to other commonly used antimicrobials 
(Table). She had 10.03 x 103/uL WBC (norm: 4–10 x 03 
uL) and high inflammatory markers: procalcitonin 
50.50 ng/mL (norm: 0.00–0.5 ng/mL), CRP 28.41 mg/dL 
(norm: 0.00–0.5 mg/dL).
Her clinical condition rapidly improved and she was 
discharged from hospital after 8 days. She had never 
been treated with colistin, did not report any previous 
close contact with farm animals and she had never 
travelled abroad.
Microbiological findings
Blood samples for cultures were collected in BD 
BACTEC culture aerobic/anaerobic vials and were incu-
bated into BACTEC FX automated blood culture system 
(Becton Dickinson and Company, Franklin Lakes, New 
Jersey, United States), according to the manufacturer’s 
instructions.
Positive blood cultures were subjected to Gram-
staining and subcultured into aerobic sheep blood agar 
plates, chocolate agar plates, selective plates and into 
Schaedler agar and 5% sheep blood plates (bioMérieux 
SA, Marcy-l’Etoile, France) anaerobically and incubated 
at 37°C overnight: the organisms were identified by 
Matrix-Assisted Laser Desorption Ionization time-of-
flight (MALDI-TOF) (Bruker Daltonics GmbH, Bremen, 
Germany).
The isolates were tested for antimicrobial susceptibil-
ity using Phoenix 100 (BD) automated system N-MIC 
panel. Isolates flagged positive for colistin resist-
ance by the system were further tested according to 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) clinical breakpoints (version 6.0) [9]. 
As recommended by EUCAST [10] and the European 
Centre for Disease Prevention and Control (ECDC) [3], 
minimal inhibitory concentration (MIC) of colistin was 
determined by broth microdiluition (UMIC colistine 
ARNIKA SRL Diagnostic Line, Milano, Italy). The MIC of 
colistin was 4 mg/L for all the isolates (≤2 susceptible, 
>2 resistant).
Only blood isolates were further tested: unfortunately, 
the urine ones, which had a similar resistance pro-
file to the isolates from blood, were not available for 
investigation.
Whole genome DNA was extracted from each isolate 
using a QIAamp DNA minikit (Qiagen) following the 
manufacturer’s instructions, and sequenced using an 
Illumina Miseq platform with a 2 by 250 paired-end run 
after Nextera XT paired-end library preparation.
Genome assembly was performed using SPAdes-3.10.1 
software. The genomic sequences were submitted 
to the European Nucleotide Archive (ENA) (accession 
Table
Antibiotic susceptibility according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical 
breakpoints [9] of clinical Eschericha coli isolates obtained from human cases with bloodstream infections, Pavia, Italy, 
August 2016–January 2017 (n = 3 cases)
MIC mg/L (S/I/R)
Case Isolation date Sequence type CST AMK AMP CAZ CTX FEP CIP FOS MEM GEN TZP SXT TGC 
Case 1 7 Aug 2016 131 4 (R) < 4 (S) ≤ 2 (S) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S)
≤ 0.25 
(S)
≤ 16 
(S)
≤ 0.125 
(S) ≤ 1 (S)
≤ 4/4 
(S)
≤ 1/19 
(S)
≤ 0.5 
(S)
Case 2 12 Aug 2016 3941 4 (R) < 4 (S) > 8 (R) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S) > 1 (R)
≤ 16 
(S)
≤ 0.125 
(S) > 4 (R)
≤ 4/4 
(S)
> 4/76 
(R)
≤ 0.5 
(S)
Case 3 22 Jan 2017 1851 4 (R) < 4 (S) > 8 (R) ≤ 0.5 (S) ≤ 1 (S) ≤ 1 (S)
≤ 0.25 
(S)
≤ 16 
(S)
≤ 0.125 
(S) ≤ 1 (S)
≤ 4/4 
(S)
> 4/76 
(R)
≤ 0.5 
(S)
AMK: amikacin; AMP: ampicillin; CAZ: ceftazidime; CIP: ciprofloxacin; CST: colistin; CTX: cefotaxime; FEP: cefepime; FOS: fosfomycin; GEN: 
gentamicin; I: intermediate; MEM: meropenem; MIC: minimum inhibitory concentration; R: resistant; S: susceptible; SXT: trimethoprim-
sulfamethoxazole; TGC: tigecycline; TZP: piperacillin–tazobactam.
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numbers pending). Multilocus sequence typing (MLST) 
profiles were obtained in silico by analysing appropri-
ate gene variants for each genome, using an in-house 
Perl script, based on the Achtman MLST scheme [11]. 
Analysis of the 7-gene MLST showed that the three iso-
lates belong to three different sequence types: ST131, 
ST3941 and ST1851 respectively.
All three E. coli isolates obtained from blood were colis-
tin-resistant. We thus searched the genomes for the 
presence of mcr-1 and mcr-2 genes as both these genes 
can confer plasmid-mediated resistance to colistin. A 
Basic Local Alignment Search Tool (BLAST) searches 
of mcr-1 (plasmid accession number KP347127) and 
mcr-2 (LT598652) against the three assemblies were 
performed. For each genome we obtained a best hit 
for mcr-1 gene with a very low number of nucleotide 
(nt) differences (2, 0 and 1 nt differences for the ST131, 
ST3941 and ST1851 strains, respectively) and no best 
hit for mcr-2. Considering that mcr-1 and mcr-2 gene 
sequences used in the analysis are very different at 
nt level (375 nt differences), the results show that all 
three genomes harboured mcr-1 and none harboured 
mcr-2.
Discussion
The occurrence of colistin resistance based on the 
plasmid-encoded mcr-1 gene in Enterobacteriaceae has 
been described in different European countries since it 
was first reported in November 2015 [3-8].
To our knowledge, our data show the first three blood-
stream infections mediated by mcr-1-encoding E. coli in 
Italy [12,13]. A limitation of our report is that we did not 
perform a systematic investigation of all bloodstream 
infections over a certain period in our hospital and we 
are thus lacking denominator data that would provide 
better insight into the frequency of the problem. A 
study is planned to retrospectively analyse all E. coli 
strains obtained in the past year in our hospital to com-
plete our data.
All three patients in our case series had underlying 
oncological diseases with different degrees of severity 
which would put them at higher risk of sepsis, however 
not at higher risk of exposure to mcr-1–positive patho-
gens. None of the patients was previously exposed 
to colistin. Except for being hospitalised at the same 
institution at different points in time over a 6-month 
period, no other epidemiological link could be deter-
mined between them. Moreover, the three mcr-1-posi-
tive isolates belonged to three different STs, indicating 
the presence of different colistin-resistant strains.
The first of the three strains belonged to ST131. This 
ST has been described by Overdevest et al. as an 
E. coli clone associated with extended-spectrum 
beta-lactamase (ESBL) production that can colonise 
patients for prolonged periods, with an estimated half-
life of 13 months [14] and by Wang et al. as a preva-
lent ST in China probably associated with a high risk 
of dissemination among E. coli [6]. In our patient, the 
ST131 E. coli did not appear to be more pathogenic.
The ST1851 is a new ST, and the draft genome assembly 
of the respective E. coli-1851 strain has been deposited 
at ENA (accession numbers pending).
All three isolates described here showed a favourable 
susceptibility profile to other classes of antimicrobi-
als and the three bloodstreams infections were rap-
idly resolved with the chosen empirical therapy. In a 
recently published article, Poirel et al. [15] describe 
how not all plasmids with an mcr-1 gene carry other 
genes encoding resistance to clinically relevant anti-
biotics, such as β-lactams, aminoglycosides, quinolo-
nes, fosfomycin, sulfonamides, and tetracyclines. In 
2016, Bernasconi et al. [16] and Prim et al. [17] also 
reported occurrence of the mcr-1 gene in pathogens 
without presence of further genes conferring resist-
ance for example to extended-spectrum cephalosphor-
ins or carbapenemase. This fact may account for the 
positive outcome of the infections described here but 
on the other side further highlights the importance of 
horizontal dissemination of mcr-1 gene-related colistin 
resistance in non-multidrug-resistant (MDR) E. coli iso-
lates of human origin.
The identification of three patients with bloodstream 
infections caused by different strains of mcr-1–positive 
E. coli detected within 6 months in a single hospital 
suggests an important and widespread problem [3]. 
Furthermore, our findings suggest that the dissemina-
tion of mcr-1-positive E. coli in Italy could be underes-
timated because isolates may be susceptible to other 
tested antibiotics and screening is often focused on 
carbapenem-resistant strains only. Moreover, in Italy, 
where the MDR bacteria are endemic, the acquisi-
tion of mcr-1 plasmid-mediated genes by other MDR 
Enterobacteriaceae could lead to a severe public health 
concern because it seriously limits treatment options 
as already reported in 2016 by Di Pilato et al. [18]. Our 
data further highlight the need of strict surveillance of 
colistin resistance even in multi-susceptible isolates.
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